Importantly, the mode of action of NovaBiotics' compounds is such that they kill rather than merely inhibit pathogens and the likelihood of acquired or transmitted pathogen resistance developing in micro-organisms which have been exposed to the peptides is highly unlikely, if not impossible.

For more on the background behind NovaBiotics' technology click here.

NovaBiotics' proprietary technology comprises peptides; biologic molecules that in nature form the cornerstone of the body's first line of defence against the spectrum of potentially harmful microbes (bacteria, fungi, viruses, protozoa) with which we come into contact daily. NovaBiotics has capitalised on the benefical properties of these natural infection-fighting agents and has engineered third-generation derivatives that can be applied for the treatment and even prevention of a range of fungal and bacterial infections.